Evidence map›Paper›PMID 26086405›Full record

ArticleNature protocols2015

Global, in situ, site-specific analysis of protein S-sulfenylation.

Jing Yang, Vinayak Gupta, Keri A Tallman, Ned A Porter, Kate S Carroll, Daniel C Liebler

Open access · greenAbstract read
In one paragraph

Article in Nature protocols, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 141 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Profiling the landscape of cysteine posttranslational modifications in brain aging and neurodegeneration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Emerging Chemical Biology of Protein Persulfidation.Antioxidants & redox signaling · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Protein interaction landscapes revealed by advanced in vivo cross-linking-mass spectrometry.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  18. Article
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jing Yang1] Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [2] Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Vinayak GuptaDepartment of Chemistry, The Scripps Research Institute, Jupiter, Florida, USA.
Keri A TallmanDepartment of Chemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Ned A PorterDepartment of Chemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Kate S CarrollDepartment of Chemistry, The Scripps Research Institute, Jupiter, Florida, USA.
Daniel C Liebler1] Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. [2] Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Vanderbilt University · USScripps Research Institute · US

Funding

Vanderbilt Proteome Characterization CenterU24CA159988 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LIEBLER, DANIEL C · 2011 to 2016
$13.9M
Probing the role of cysteine sulfenylation in cell signalingR01GM102187 · NIGMS · UNIVERSITY OF FLORIDA · PI Kate Suzanne Carroll · 2012 to 2026
$4.6M
SLOS and Neuronal Oxidative StressR01HD064727 · NICHD · VANDERBILT UNIVERSITY · PI PORTER, NED ALLEN · 2010 to 2020
$3.7M
Nucleophilic Inhibitors for Targeting Redox-Sensitive KinasesR01CA174864 · NCI · SCRIPPS FLORIDA · PI CARROLL, KATE SUZANNE · 2014 to 2017
$1.6M
NCI NIH HHS R01 CA174864NCI NIH HHS U24 CA159988NCI NIH HHS U24CA159988NICHD NIH HHS R01 HD064727NIGMS NIH HHS R01 GM102187NIGMS NIH HHS R01GM102187
6 · The paper itself

Abstract

Protein S-sulfenylation is the reversible oxidative modification of cysteine thiol groups to form cysteine S-sulfenic acids. Mapping the specific sites of protein S-sulfenylation onto complex proteomes is crucial to understanding the molecular mechanisms controlling redox signaling and regulation. This protocol describes global, in situ, site-specific analysis of protein S-sulfenylation using sulfenic acid-specific chemical probes and mass spectrometry (MS)-based proteomics. The major steps in this protocol are as follows: (i) optimization of conditions for selective labeling of cysteine S-sulfenic acids in intact cells with the commercially available dimedone-based probe, DYn-2; (ii) tagging the modified cysteines with a functionalized biotin reagent containing a cleavable linker via Cu(I)-catalyzed azide-alkyne cycloaddition reaction; (iii) enrichment of the biotin-tagged tryptic peptides with streptavidin; (iv) liquid chromatography-tandem MS (LC-MS/MS)-based shotgun proteomics; and (v) computational data analysis. We also outline strategies for quantitative analysis of this modification in cells responding to redox perturbations and discuss special issues pertaining to experimental design of thiol redox studies. Our chemoproteomic platform should be broadly applicable to the investigation of other bio-orthogonal chemically engineered post-translational modifications. The entire analysis protocol takes ∼1 week to complete.

Indexed as

Cell LineHumansOxidation-ReductionProtein Processing, Post-TranslationalProteinsProteomicsSulfenic AcidsTandem Mass SpectrometryProteinsSulfenic Acids

Identifiers

PMID26086405
PMCPMC4608369
OpenAlexW1514298620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.